GlassScriptPhysician profile
Michael Baluyut
NPI 1336226067
$3,856.99
in general payments reported to CMS, 2019-2025
25 companies · $999 in 2025
The $999 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $409 · 2021: $495 · 2022: $337 · 2023: $417 · 2024: $532 · 2025: $999.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,948.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $772.81 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $767.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $331.76 | 2021-2025 | Krystexxa, Repatha, Otezla |
| Novo Nordisk INC | $278.37 | 2021-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $271.82 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $195.35 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $183.85 | 2019-2021 | |
| Pfizer INC. | $148.14 | 2019-2025 | |
| Lilly USA, LLC | $133.14 | 2020-2025 | Jardiance, Emgality, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $131.80 | 2019-2022 | |
| Edwards Lifesciences Corporation | $96.72 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Ardelyx, INC. | $94.26 | 2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $92.02 | 2019-2020 | |
| Abbott Laboratories | $58.78 | 2021 | |
| Abiomed | $47.35 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $45.82 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $36.65 | 2019 | |
| Dexcom, INC. | $28.38 | 2024 | Dexcom G6 Transmitter |
| Metacel Pharmaceuticals LLC | $24.06 | 2023 | Ozobax |
| Xeris Pharmaceuticals, INC. | $22.65 | 2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $22.37 | 2021 | |
| Arbor Pharmaceuticals, INC. | $22.03 | 2019 | |
| Medline Industries LP | $20.00 | 2025 | |
| Esperion Therapeutics, INC. | $16.78 | 2021 | |
| Horizon Therapeutics Plc | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Baluyut listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.